|Table of Contents|

The exprssion of CA199，CA153 and CYFRA21-1 in non-small cell lung cancer tissues and its correlation with clinicopathological features

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 03
Page:
418-422
Research Field:
Publishing date:

Info

Title:
The exprssion of CA199，CA153 and CYFRA21-1 in non-small cell lung cancer tissues and its correlation with clinicopathological features
Author(s):
HU Chengwei1; GUO Jiuling2; LI Dongxia2; YANG Xiaohui3; ZHENG Hongxia2
1.Department of Clinical Laboratory，the No.5 People's Hospital of Hengshui,Hebei Hengshui 053000，China；2.Department of Clinical Laboratory；3.Department of Oncology，the No.2 People's Hospital of Hengshui,Hebei Hengshui 053000，China.
Keywords:
non-small cell lung cancer; carbohydrate antigen 199; carbohydrate antigen 153; cytokeratin 19 fragment antigen
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.03.012
Abstract:
Objective：To investigate the expression of carbohydrate antigen 199(CA199)，carbohydrate antigen 153(CA153) and cytokeratin 19 fragment antigen(CYFRA21-1) in non-small cell lung cancer tissues and its correlation with clinicopathological features.Methods：We selected 50 patients who received surgical treatment in No.2 People's Hospital of Hengshui from January 2016 to June 2017，and made specimens from all the patients' cancer tissues and the para-cancerous tissues which were more than 5 cm away from the cancer tissues.The specimens were stained by immunohistochemistry.The expression of CA199，CA153 and CYFRA21-1 was detected by chemiluminescence method.Results：The expression of CA199，CA153 and CYFRA21-1 in cancer tissues were significantly higher than those in para-cancerous tissues(P<0.05).The expressions of CA199，CA153 and CYFRA21-1 in patients with tumor volume(≥5 cm3) were significantly higher than those in patients with tumor volume(<5 cm3)(P<0.05).The expression of CA199，CA153 and CYFRA21-1 in serous invasion patients were significantly higher than those in missed serous invasion patients(P<0.05).The expression of CA199，CA153 and CYFRA21-1 in patients with pathological stage Ⅲ and Ⅳ were significantly higher than those in patients with pathological stage Ⅰ and Ⅱ(P<0.05).The expression of CA199，CA153 and CYFRA21-1 in patients with lymph node metastasis were significantly higher than those in patients without lymph node metastasis(P<0.05).The expression of CA199，CA153 and CYFRA21-1 in poorly differentiated patients were higher than those in moderately differentiated patients，and the expression of CA199，CA153 and CYFRA21-1 in moderately differentiated patients were higher than those in well differentiated patients(P<0.05).Conclusion：CA199，CA153 and CYFRA21-1 were highly expressed in non-small cell lung cancer tissues，and they were correlated with clinicopathological parameters such as tumor volume，invasion degree，pathological stage，lymph node metastasis and differentiation degree，and were closely related to the occurrence and evolution of non-small cell lung cancer.

References:

[1]吉晓剑，杨秀林，周厚荣，等.泛素特异性蛋白酶39在非小细胞肺癌中的表达及其对细胞增殖的影响［J］.中国现代医学杂志，2018，28(30)：37-42. JI XJ，YANG XL，ZHOU HR，et al.Effect of USP39 in non-small cell lung cancer［J］.Chinese Journal of Modern Medicine，2018，28(30)：37-42.
[2]WEI T，ZHU D，YANG Y，et al.The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer(NSCLC) treatment［J］.PLoS One，2019，14(7)：e0219129.
[3]陈晓，魏立，陈重，等.CD8+CD103+肿瘤浸润淋巴细胞在非小细胞肺癌中的表达及意义［J］.实用癌症杂志，2018，33(7)：1049-1052. CHEN X，WEI L，CHEN C，et al.Expression and significance of CD8+CD103+ tumor infiltrating lymphocytes in non-small cell lung cancer［J］.Journal of Practical Cancer，2018，33(7)：1049-1052.
[4]LI R，LIN J，WANG L，et al.The association between 18F-fluorodeoxyglucose PET intratumoral metabolic heterogeneity and pathological parameters in non-small cell lung cancer［J］.Nucl Med Commun，2019，40(10)：1022-1028.
[5]傅杨，夏西燕，李晓慧，等.非小细胞肺癌组织中Syncytin-1的表达变化及与患者预后的关系［J］.山东医药，2018，58(29)：25-28. FU Y，XIA XY，LI XH，et al.Expression of Syncytin-1 in non-small-cell lung cancer and its relationship with prognosis［J］.Shandong Medical Journal，2018，58(29)：25-28.
[6]陈鹏，赵景岚，鲁瑞珍，等.非小细胞肺癌组织中TAZ、YAP蛋白表达变化及意义［J］.山东医药，2018，58(21)：61-63. CHEN P，ZHAO JL，LU RZ，et al.Changes and significance of TAZ and YAP protein expression in non-small cell lung cancer［J］.Shandong Medicine，2018，58(21)：61-63.
[7]宋宣克，冯怡锟，苏彦河,等.表皮生长因子受体、糖类抗原125、糖类抗原199在非小细胞肺癌术后骨转移中的表达及意义［J］.中华实验外科杂志，2016，33(5)：1381-1383. SONG XK，FENG YK，SU YH，et al.Expression of epidermal growth factor receptor，carbohydrate antigen 125，and carbohydrateantigen 199 in postoperative non-small cell lung cancer patients with bone metastasis［J］.Chinese Journal of Experimental Surgery，2016，33(5)：1381-1383.
[8]杨福利，王继松，牟坤，等.非小细胞肺癌患者表皮生长因子受体突变与血清癌胚抗原和糖类抗原检测的关系［J］.中国临床保健杂志，2016，19(2)：132-134. YANG FL，WANG JS，MOU K，et al.Relationship between EGFR mutation and detection of carcinoembryonic antigen and carbohydrate antigen in serum of patients with non-small cell lung cancer［J］.Chinese Journal of Clinical Health Care，2016，19(2)：132-134.
[9]茅肖娜，汪莉莉.血清miR-21和CA199对胰腺癌临床诊断的应用价值探讨［J］.重庆医学，2018，47(17)：2319-2322. MAO XN，WANG LL.The value of serum miR-21 and CA199 in the clinical diagnosis of pancreatic cancer［J］.Chongqing Medical Journal，2018，47(17)：2319-2322.
[10]邱绪文，王祖斌.血清CEA、CA199、CA724、CA242与结直肠癌关系的临床研究［J］.中国现代普通外科进展，2016，19(4)：326-327，330. QIU XW，WANG ZB.Clinical study on the relationship between serum CEA，CA199，CA724，CA242 and colorectal cancer［J］.Progress of Modern General Surgery in China，2016，19(4)：326-327，330.
[11]汪硕敏，顾康生.血清癌胚抗原、铁蛋白和糖基抗原199在非小细胞肺癌诊断中的临床价值［J］.安徽医科大学学报，2018，53(9)：1444-1447. WANG SM，GU KS.Clinical value of serum carcinoembryonic antigen，ferritin and glycosyl antigen 199 in the diagnosis of non-small cell lung cancer［J］.Journal of Anhui Medical University，2018，53(9)：1444-1447.
[12]黄汉琮，陈乾华，杨晓蕊，等.CA199、TMPRSS4在早期非小细胞肺癌组织的表达及在肿瘤血管形成中的作用［J］.中国老年学杂志，2019，39(4)：817-818. HUANG HC，CHEN QH，YANG XR，et al.Expression of CA199 and TMPRSS4 in early NSCLC and their role in tumor angiogenesis［J］.Chin J Gerontol，2019，39(4)：817-818.
[13]徐龙，张冠中，郑振东，等.血清CEA及CA153连续且显著降低对晚期乳腺癌无影像学进展的判定价值［J］.中国肿瘤临床，2016，43(19)：865-868. XU L，ZHANG GZ，ZHENG ZD，et al.The continuous and significant decrease of serum CEA and CA153 in the judgment of no imaging progress of advanced breast cancer［J］.Chin J Oncol，2016，43(19)：865-868.
[14]南永刚，许建林，李楠，等.CA153、CA125联合HER－2检测在乳腺癌各临床分期诊断中的应用［J］.现代肿瘤医学，2016，24(19)：3070-3073. NAN YG，XU JL，LI N，et al.The application of CA153，CA125 combined with HER-2 detection in the diagnosis of breast cancer in different clinical stages［J］.Modern Oncology，2016，24(19)：3070-3073.
[15]何克钢.肺癌临床诊断中肿瘤标志物CA153、CA125检验应用的价值分析［J］.现代诊断与治疗，2016，27(11)：2102-2103. HE KG.Analysis of the value of CA153 and CA125 in the clinical diagnosis of lung cancer［J］.Modern Diagnosis and Treatment，2016，27(11)：2102-2103.
[16]刘志强，王湘毅，孙晓革，等.CA125，CA153及 CEA肿瘤标志物联合检测对非小细胞肺癌早期诊断的临床意义［J］.临床合理用药杂志，2016，9(5)：111-112. LIU ZQ，WANG XY，SUN XG，et al.The clinical significance of combined detection of CA125，CA153 and CEA tumor markers in the early diagnosis of NSCLC［J］.Journal of Clinical Rational Drug Use，2016，9(5)：111-112.
[17]黄冬云，许文景，周锐，等.血清 CYFRA21－1、NSE 和 CEA 在非小细胞肺癌辅助诊断中的应用［J］.中国老年学杂志，2016，36(6)：1378-1380. HUANG DY，XU WJ，ZHOU R，et al.Application of serum CYFRA21-1，NSE and CEA in the auxiliary diagnosis of NSCLC［J］.Chin J Gerontol，2016，36(6)：1378-1380.
[18]杜军华，乔洪源，尹宜发，等.血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响［J］.肿瘤防治研究，2016，43(2)：137-140. DU JH，QIAO HY，YIN YF，et al.The influence of serum CEA，CA125 and Cyfra21-1 levels on the prognosis of patients with advanced non-small cell lung cancer［J］.Cancer Prevention and Treatment Research，2016，43(2)：137-140.
[19]鲁丹，万彦彬，赖馨，等.血清 CEA、NSE、CYFRA21-1水平与非小细胞肺癌病理分期的相关性［J］.中国实验诊断学，2016，20(6)：912-914. LU D，WAN YB，LAI X，et al.Correlation between serum CEA，NSE，CYFRA21-1 levels and pathological stages of NSCLC［J］.Chinese Journal of Experimental Diagnostics，2016，20(6)：912-914.
[20]陆友国，叶兵，夏丽丽，等.CYFRA21-1、β2-MG和SCC-Ag表达水平与晚期非小细胞肺癌化疗疗效及预后的关系分析［J］.标记免疫分析与临床，2018，25(11)：1716-1720. LU YG，YE B，XIA LL，et al.Analysis of the relationship between the expression levels of CYFRA21-1，β2-MG and SCC-Ag and the chemotherapy efficacy and prognosis of advanced non-small cell lung cancer［J］.Marker Immunoassay and Clinical，2018，25(11)：1716-1720.

Memo

Memo:
衡水市科技厅项目（编号：2017014017Z）
Last Update: 2020-12-31